Curis (CRIS) Share-based Compensation (2010 - 2026)
Curis' (CRIS) quarterly Share-based Compensation came in at $569000.0 in Q2 2026, down 49.87% on a YoY basis from $1.1 million in Q2 2025, and down 1.04% quarter-over-quarter from $575000.0 in Q1 2026.
Analysis
Curis (CRIS) Share-based Compensation (2010 - 2026) Analysis & Trends
Curis (CRIS) has reported Share-based Compensation for 17 consecutive years, with $569000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation fell 49.87% year-over-year to $569000.0; the trailing twelve-month figure through Jun 2026 stood at $2.9 million (down 42.31% YoY), and the FY2025 full-year result was $4.0 million, down 32.21% from the prior year.
- Share-based Compensation fell to $569000.0 in Q2 2026 per CRIS's latest filing, from $575000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.0 million in Q2 2022 and bottomed at $569000.0 in Q2 2026.
- Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $1.4 million in 2023.
- The sharpest annual moves came in 2022 and 2026: Share-based Compensation surged 56.32% in 2022, then plunged 50.6% in 2026.
- Over 5 years, Share-based Compensation stood at $1.7 million in 2022, then fell by 11.24% to $1.5 million in 2023, then declined by 17.31% to $1.3 million in 2024, then sank by 37.89% to $795000.0 in 2025, then retreated by 28.43% to $569000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $569000.0, $575000.0, and $795000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Curis | 2.57 Mn | -3.05 Mn | - | 569,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 569,000.00 |
| Mar 31, 2026 | 575,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Sep 30, 2025 | 924,000.00 |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 1.74 Mn |
| Sep 30, 2022 | 1.32 Mn |
| Jun 30, 2022 | 1.97 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Sep 30, 2021 | 1.46 Mn |